Literature DB >> 9740847

[Scleredema, acanthosis nigricans and IgA/Kappa multiple myeloma].

L Valente1, G C Velho, F Farinha, A Bernardo, P Ribeiro, A Massa.   

Abstract

BACKGROUND: Scleredema is an uncommon disease of unknown origin. Characteristic thick skin with symmetrical diffuse induration develops. The infiltration begins on the face and neck then extends to the root of the upper limbs and trunk. There are three clinical types of scleredema. The first is preceded by an upper airway infection and progresses rapidly before regressing spontaneously within a few months. The second type is associated with chronic diabetes. The third type is associated with monoclonal gammapathy, rarely of myelomatous type, and develops insidiously. Acanthosis nigricans can be a paraneoplastic syndrome, often associated with a gastrointestinal cancer. Few cases associating scleredema and acanathosis nigricans have been reported. CASE REPORT: A 56-year old woman had developed scleredema over the last 6 years when acanthosis nigricans appeared together with IgA kappa multiple myeloma. Treatment with melphalan and prednisolone was effective against the myeloma as well as the scleredema and acanthosis nigricans. DISCUSSION: Only five cases of associated scleredema and multiple myeloma have been reported, four with kappa IgG myeloma and one with IgA myeloma. An association between acanthosis nigricans and sclerederma could be coincidental although the fact that the different manifestations regressed together after the myeloma treatment would suggest some relationship between these three diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9740847

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  4 in total

1.  Coexistence of scleroderma with multiple myeloma: a rare association.

Authors:  Smeeta Gajendra; Richa Gupta; Ritu Gupta; Lalit Kumar
Journal:  BMJ Case Rep       Date:  2013-09-10

2.  SCLEREDEMA.

Authors:  Y K Sharma; S Baveja; A Khetarpal
Journal:  Med J Armed Forces India       Date:  2017-06-12

Review 3.  FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature.

Authors:  Milica Čolović; Vladimir Jurisic; Jelena Bila; Natasa Čolović; Vuk Palibrk
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

Review 4.  From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature.

Authors:  Magdalena Dziadzio; Constantinos P Anastassiades; Philip N Hawkins; Michael Potter; Armando Gabrielli; Geraldine M Brough; Carol M Black; Christopher P Denton
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.